SecBot SecBot
S-4 ·Filed Jul 2, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001193125-26-294455
Notable filing: S-4
Actionable Insight ▼ Bearish

InMed shareholders face near-total dilution and should consider the high risk of deal failure or CVRs expiring worthless. Monitor the shareholder vote and Nasdaq listing condition; if the merger closes, the stock will effectively become a vehicle for Mentari's pipeline.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

INM drug pipeline →

MT-001

● Neutral Named in this S-4
Impact
Phase
Preclinical (IND-enabling)
Time to market
Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Next catalyst
None dated

What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.56
T+0 close · Jul 2, 2026 · via day close
Latest settled
−12.82%
T+60 · $1.36
Vs SPY
−16.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $1.56entry
  2. T+1 · 4mo ago +3.21%α +2.33% · $1.61
  3. T+5 · 4mo ago +6.41%α +5.48% · $1.66
  4. T+20 · 4mo ago −3.85%α −3.43% · $1.50
  5. T+60 · 7w ago −12.82%α −16.39% · $1.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics. The deal is structured as a reverse merger in which InMed shareholders will own only ~1.51% of the combined company, while Mentari securityholders (including investors in a $290M pre-closing financing) will own ~98.49%. InMed's legacy business will be wound down, and shareholders will receive contingent value rights (CVRs) with uncertain payoff. The merger is expected to close in Q3 2026, subject to shareholder and regulatory approvals.

Key Facts

  • InMed shareholders will own approximately 1.51% of the combined company post-merger.
  • Mentari securityholders (including $290M pre-closing financing investors) will own approximately 98.49%.
  • InMed is winding down its only revenue-generating segment (BayMedica) and faces going-concern uncertainty.
  • InMed shareholders will receive CVRs tied to disposition of legacy assets, which may be valueless.
  • The merger is conditioned on Nasdaq listing approval for the combined company's stock under symbol MTRI.
  • InMed board recommends voting for all proposals; if merger fails, InMed may liquidate.

Financial Impact

Massive dilution for InMed shareholders: ownership drops from 100% to ~1.51%. The $290M pre-closing financing values Mentari at a substantial premium to InMed's current market cap of $4M.

ownershipdilutionmarket capitalization

Risk Factors

  • Merger may fail to close due to shareholder disapproval or Nasdaq listing issues.
  • CVRs may never pay out if legacy assets are not monetized.
  • Combined company will need substantial additional capital post-merger.
  • InMed's stock may be delisted if Nasdaq conditions are not met.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
S-4 Filing (Primary)0001193125-26-294455
Document: d131177dex32.htm0001193125-26-294455
Document: d131177dex1022.htm0001193125-26-294455
Document: d131177dex420.htm0001193125-26-294455

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026